A prescriber submits a request, a reviewer compares it to a written criteria document, and an answer comes back inside a defined window. The detail that trips people up is that the criteria document is chosen by indication. Tirzepatide has two approved indications, so there are two possible paths and they are not interchangeable.
The request is built around an indication, not a drug name
Zepbound is approved both for reducing and maintaining body weight in adults with obesity or overweight with a weight-related condition, and for treating moderate to severe obstructive sleep apnea in adults with obesity. The sleep apnea use came from a randomized trial in adults with OSA and obesity and was the first drug clearance for that condition.
Reviewers do not evaluate molecules in the abstract. They open the criteria set attached to the diagnosis on the request. Two people can be prescribed the identical product on the same day and be judged against different standards, different documentation and different specialties, because the diagnosis on the form differs. Deciding which indication a case genuinely falls under, before anything is filed, is the single highest-value step in the whole process.
Identify the licensee, the sponsor and the benefit manager
Anthem is a Blue Cross Blue Shield licensee, operated locally in the states where it holds the license and sitting under the Elevance Health corporate umbrella. Behind it sits a plan sponsor, and for most large employers that sponsor self-funds, meaning it pays claims from its own money and chooses the benefit design. Behind that again sits a pharmacy benefit manager that runs the drug list and often the review itself.
Three entities, three sets of documents. The member ID card names the administrator and usually the pharmacy benefit manager. The employer’s benefits portal holds the plan document. Requests get routed correctly far more often when the office knows which of the three it is actually addressing.
Where the criteria document lives
Drug lists are published. So, generally, are the criteria attached to drugs that require review, though they sit one layer deeper and are usually organized by policy number rather than by product name. Members can request the criteria applied to their own case. Reading it beforehand converts guesswork into a checklist, since every element the reviewer will look for is written there in the plan’s own words.
Criteria differ between sponsors, between plan options and between years. Anything found in a forum, a screenshot or a prior year’s document is a lead rather than a rule. The governing version is the one the plan publishes for the current year.
| Element | Weight-management path | Sleep apnea path |
|---|---|---|
| Diagnosis on the request | Obesity, or overweight with a related condition | Moderate to severe OSA with obesity |
| Usual submitting office | Primary care or obesity medicine | Sleep medicine, pulmonology or primary care |
| Records the reviewer opens | Weight-management chart history | Diagnostic testing and sleep history |
| Criteria document | The policy tied to that indication | A separate policy for that indication |
| Effect of a weight-loss exclusion | Blocks the request | Not automatically applicable |
Who assembles what
The prescribing office files the request and holds the clinical record, so it does the substantive work. The member’s job is smaller but not trivial: confirm which plan applies, obtain the criteria document, supply outside records the office does not hold, and keep dated proof of every submission. Pharmacy fill histories, prior test results and records from a previous practice usually have to come from the member, because no one else can produce them quickly.
What happens while the review runs
Nothing dispenses without an approval on file, so the prescription sits. Where a delay would put health at risk, an expedited review can be requested by the clinician on those grounds, not by the member on grounds of inconvenience. Some offices also request a peer-to-peer discussion, which puts the prescriber in front of the reviewing clinician and can resolve a documentation dispute faster than a written resubmission.
People often price a fallback while waiting rather than after a refusal. Manufacturer self-pay pharmacies publish figures for the approved products, and cash practices including Ro, Hims and Hers, LifeMD and FormBlends publish monthly program pricing. A posted monthly number only means something once a reader knows what is inside it and the provider behind it, including who reviews the case and whether refills sit inside the quoted figure. Compounded preparations are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality.
Approvals expire, and renewal is a second review
An authorization carries an effective period. When it ends, continuation is assessed again, often against criteria written for continued therapy rather than for starting. Trial evidence on maintenance shows the effect is tied to staying on treatment, which makes a lapsed authorization a clinical event rather than a paperwork one. Calendar the expiry date the day the approval arrives.
If a renewal review goes the wrong way, that calendar entry also buys time to compare what the self-pay market charges before the current supply runs out. Manufacturer routes like LillyDirect sell the brand directly, while telehealth providers such as Henry Meds, Ro and HealthRX post their own pages for Zepbound and the wider GLP-1 category. Reading two or three of those against each other tells a person more than reacting to a single number at the pharmacy counter.
Questions people ask
Can a request be filed under both indications at once?
Requests are reviewed one indication at a time, because each has its own criteria set and its own required records. Where a patient genuinely meets more than one, the office decides which is better documented and files that. A second request under the other indication remains available afterward.
Does approval mean the medication is affordable?
Not by itself. Approval settles whether the plan will pay anything; the tier, the deductible position and the coinsurance settle what the member pays. Those are separate variables published in different documents, and a covered drug can still carry a monthly cost that changes the decision.
Who should call the plan, the member or the office?
Both, for different things. The office discusses clinical criteria and files the request. The member confirms eligibility, obtains the criteria document and chases status, which offices rarely have time to do daily. Splitting it that way avoids the loop where each side assumes the other is calling.
What if the plan takes longer than its stated window?
Federal standards set outer limits, with shorter clocks for urgent requests. A plan that misses its own deadline can open procedural options later in the appeal process. That argument only exists if the member kept dated records of what was sent and when it was acknowledged.
